Cargando…

Whole blood FPR1 mRNA expression predicts both non‐small cell and small cell lung cancer

While long‐term survival rates for early‐stage lung cancer are high, most cases are diagnosed in later stages that can negatively impact survival rates. We aim to design a simple, single biomarker blood test for early‐stage lung cancer that is robust to preclinical variables and can be readily imple...

Descripción completa

Detalles Bibliográficos
Autores principales: Morris, Scott, Vachani, Anil, Pass, Harvey I., Rom, William N., Ryden, Kirk, Weiss, Glen J., Hogarth, D. K., Runger, George, Richards, Donald, Shelton, Troy, Mallery, David W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901395/
https://www.ncbi.nlm.nih.gov/pubmed/29313979
http://dx.doi.org/10.1002/ijc.31245
_version_ 1783314607057666048
author Morris, Scott
Vachani, Anil
Pass, Harvey I.
Rom, William N.
Ryden, Kirk
Weiss, Glen J.
Hogarth, D. K.
Runger, George
Richards, Donald
Shelton, Troy
Mallery, David W.
author_facet Morris, Scott
Vachani, Anil
Pass, Harvey I.
Rom, William N.
Ryden, Kirk
Weiss, Glen J.
Hogarth, D. K.
Runger, George
Richards, Donald
Shelton, Troy
Mallery, David W.
author_sort Morris, Scott
collection PubMed
description While long‐term survival rates for early‐stage lung cancer are high, most cases are diagnosed in later stages that can negatively impact survival rates. We aim to design a simple, single biomarker blood test for early‐stage lung cancer that is robust to preclinical variables and can be readily implemented in the clinic. Whole blood was collected in PAXgene tubes from a training set of 29 patients, and a validation set of 260 patients, of which samples from 58 patients were prospectively collected in a clinical trial specifically for our study. After RNA was extracted, the expressions of FPR1 and a reference gene were quantified by an automated one‐step Taqman RT‐PCR assay. Elevated levels of FPR1 mRNA in whole blood predicted lung cancer status with a sensitivity of 55% and a specificity of 87% on all validation specimens. The prospectively collected specimens had a significantly higher 68% sensitivity and 89% specificity. Results from patients with benign nodules were similar to healthy volunteers. No meaningful correlation was present between our test results and any clinical characteristic other than lung cancer diagnosis. FPR1 mRNA levels in whole blood can predict the presence of lung cancer. Using this as a reflex test for positive lung cancer screening computed tomography scans has the potential to increase the positive predictive value. This marker can be easily measured in an automated process utilizing off‐the‐shelf equipment and reagents. Further work is justified to explain the source of this biomarker.
format Online
Article
Text
id pubmed-5901395
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-59013952018-04-24 Whole blood FPR1 mRNA expression predicts both non‐small cell and small cell lung cancer Morris, Scott Vachani, Anil Pass, Harvey I. Rom, William N. Ryden, Kirk Weiss, Glen J. Hogarth, D. K. Runger, George Richards, Donald Shelton, Troy Mallery, David W. Int J Cancer Tumor Markers and Signatures While long‐term survival rates for early‐stage lung cancer are high, most cases are diagnosed in later stages that can negatively impact survival rates. We aim to design a simple, single biomarker blood test for early‐stage lung cancer that is robust to preclinical variables and can be readily implemented in the clinic. Whole blood was collected in PAXgene tubes from a training set of 29 patients, and a validation set of 260 patients, of which samples from 58 patients were prospectively collected in a clinical trial specifically for our study. After RNA was extracted, the expressions of FPR1 and a reference gene were quantified by an automated one‐step Taqman RT‐PCR assay. Elevated levels of FPR1 mRNA in whole blood predicted lung cancer status with a sensitivity of 55% and a specificity of 87% on all validation specimens. The prospectively collected specimens had a significantly higher 68% sensitivity and 89% specificity. Results from patients with benign nodules were similar to healthy volunteers. No meaningful correlation was present between our test results and any clinical characteristic other than lung cancer diagnosis. FPR1 mRNA levels in whole blood can predict the presence of lung cancer. Using this as a reflex test for positive lung cancer screening computed tomography scans has the potential to increase the positive predictive value. This marker can be easily measured in an automated process utilizing off‐the‐shelf equipment and reagents. Further work is justified to explain the source of this biomarker. John Wiley and Sons Inc. 2018-01-30 2018-06-01 /pmc/articles/PMC5901395/ /pubmed/29313979 http://dx.doi.org/10.1002/ijc.31245 Text en © 2018 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Tumor Markers and Signatures
Morris, Scott
Vachani, Anil
Pass, Harvey I.
Rom, William N.
Ryden, Kirk
Weiss, Glen J.
Hogarth, D. K.
Runger, George
Richards, Donald
Shelton, Troy
Mallery, David W.
Whole blood FPR1 mRNA expression predicts both non‐small cell and small cell lung cancer
title Whole blood FPR1 mRNA expression predicts both non‐small cell and small cell lung cancer
title_full Whole blood FPR1 mRNA expression predicts both non‐small cell and small cell lung cancer
title_fullStr Whole blood FPR1 mRNA expression predicts both non‐small cell and small cell lung cancer
title_full_unstemmed Whole blood FPR1 mRNA expression predicts both non‐small cell and small cell lung cancer
title_short Whole blood FPR1 mRNA expression predicts both non‐small cell and small cell lung cancer
title_sort whole blood fpr1 mrna expression predicts both non‐small cell and small cell lung cancer
topic Tumor Markers and Signatures
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901395/
https://www.ncbi.nlm.nih.gov/pubmed/29313979
http://dx.doi.org/10.1002/ijc.31245
work_keys_str_mv AT morrisscott wholebloodfpr1mrnaexpressionpredictsbothnonsmallcellandsmallcelllungcancer
AT vachanianil wholebloodfpr1mrnaexpressionpredictsbothnonsmallcellandsmallcelllungcancer
AT passharveyi wholebloodfpr1mrnaexpressionpredictsbothnonsmallcellandsmallcelllungcancer
AT romwilliamn wholebloodfpr1mrnaexpressionpredictsbothnonsmallcellandsmallcelllungcancer
AT rydenkirk wholebloodfpr1mrnaexpressionpredictsbothnonsmallcellandsmallcelllungcancer
AT weissglenj wholebloodfpr1mrnaexpressionpredictsbothnonsmallcellandsmallcelllungcancer
AT hogarthdk wholebloodfpr1mrnaexpressionpredictsbothnonsmallcellandsmallcelllungcancer
AT rungergeorge wholebloodfpr1mrnaexpressionpredictsbothnonsmallcellandsmallcelllungcancer
AT richardsdonald wholebloodfpr1mrnaexpressionpredictsbothnonsmallcellandsmallcelllungcancer
AT sheltontroy wholebloodfpr1mrnaexpressionpredictsbothnonsmallcellandsmallcelllungcancer
AT mallerydavidw wholebloodfpr1mrnaexpressionpredictsbothnonsmallcellandsmallcelllungcancer